NO20065146L - Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin - Google Patents

Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin

Info

Publication number
NO20065146L
NO20065146L NO20065146A NO20065146A NO20065146L NO 20065146 L NO20065146 L NO 20065146L NO 20065146 A NO20065146 A NO 20065146A NO 20065146 A NO20065146 A NO 20065146A NO 20065146 L NO20065146 L NO 20065146L
Authority
NO
Norway
Prior art keywords
atorvastatin
preparation
butyl ester
polymorphs
intermediates
Prior art date
Application number
NO20065146A
Other languages
English (en)
Norwegian (no)
Inventor
Rok Zupet
Matej Smrkolj
Anton Stimac
Marija Grcman
Renata Jakse
Original Assignee
Krka Tovarna Zdravil Dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka Tovarna Zdravil Dd filed Critical Krka Tovarna Zdravil Dd
Publication of NO20065146L publication Critical patent/NO20065146L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20065146A 2004-04-09 2006-11-08 Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin NO20065146L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400112A SI21745A (sl) 2004-04-09 2004-04-09 Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
PCT/EP2005/003733 WO2005097742A1 (fr) 2004-04-09 2005-04-08 Polymorphes d'ester de tert-butyle d'atorvastatine et leur utilisation en tant qu'intermediaires dans la preparation d'atorvastatine

Publications (1)

Publication Number Publication Date
NO20065146L true NO20065146L (no) 2006-11-08

Family

ID=34963800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065146A NO20065146L (no) 2004-04-09 2006-11-08 Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin

Country Status (15)

Country Link
EP (1) EP1732886B1 (fr)
CN (2) CN101538238B (fr)
AT (1) ATE459602T1 (fr)
DE (1) DE602005019703D1 (fr)
DK (1) DK1732886T3 (fr)
EA (1) EA010166B1 (fr)
ES (1) ES2339570T3 (fr)
HR (1) HRP20100217T1 (fr)
NO (1) NO20065146L (fr)
PL (1) PL1732886T3 (fr)
PT (1) PT1732886E (fr)
RS (1) RS51259B (fr)
SI (2) SI21745A (fr)
UA (1) UA86059C2 (fr)
WO (1) WO2005097742A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US20090081801A1 (en) * 2007-08-15 2009-03-26 Vinod Kumar Kansal Process for synthesis of pyrrole derivative, an intermediate for atorvastatin
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
SI2413911T1 (sl) 2009-03-31 2014-04-30 Krka, D.D., Novo Mesto Progresivna emulzijska kristalizacija
CN105693587A (zh) * 2016-01-15 2016-06-22 安徽悦康凯悦制药有限公司 一种阿托伐他汀钙的生产工艺
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
SK7212003A3 (en) * 2000-11-16 2004-03-02 Teva Pharma Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
IL160077A0 (en) * 2001-08-16 2004-06-20 Teva Pharma Processes for preparing calcium salt forms of statins

Also Published As

Publication number Publication date
EA200601651A1 (ru) 2007-02-27
CN101538238A (zh) 2009-09-23
DE602005019703D1 (de) 2010-04-15
EA010166B1 (ru) 2008-06-30
PL1732886T3 (pl) 2010-08-31
SI1732886T1 (sl) 2010-06-30
CN1946687B (zh) 2011-09-28
DK1732886T3 (da) 2010-06-14
ATE459602T1 (de) 2010-03-15
CN101538238B (zh) 2012-08-29
EP1732886B1 (fr) 2010-03-03
SI21745A (sl) 2005-10-31
ES2339570T3 (es) 2010-05-21
EP1732886A1 (fr) 2006-12-20
PT1732886E (pt) 2010-03-12
UA86059C2 (ru) 2009-03-25
CN1946687A (zh) 2007-04-11
RS51259B (sr) 2010-12-31
HRP20100217T1 (hr) 2010-05-31
WO2005097742A1 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
NO20065146L (no) Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin
WO2003086306A3 (fr) Modulateurs du recepteur 5ht2c
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20075809L (no) DNA-PK inhibitorer
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
NO20072930L (no) Tripentylcitrater og deres anvendelse
EP1416933B8 (fr) Piperidines substituees utilisees comme modulateurs du recepteur de la melanocortine
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
TW200734311A (en) New compounds
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
GEP20074078B (en) Fluoro substituted cyclo-alkanoindoles, compositions comprising them and their use
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20082496L (no) Pyrazinderivater
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
NO20065046L (no) Krystallinsk polymorf av bazedoksifenacetat
WO2005075467A3 (fr) Formes cristallines de zolmitriptan
DK2229949T3 (da) Anvendelse af mælkesyrebakterier til nedsættelse af tandkødsblødning og reduktion af mundbetændelse
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
TNSN07165A1 (en) Organic compounds
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application